Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.

Docetaxel without prednisone ineffective for preventing prostate cancer progression after RT

28 Nov 2019

In prostate cancer patients who had undergone radical radiotherapy (RT), adjuvant docetaxel does not improve biochemical disease-free survival in the absence of prednisone, a recent study has found.

Researchers randomly assigned 376 prostate cancer patients to undergo either six cycles of adjuvant docetaxel (75 mg/m2 every 3 weeks; n=188; median age, 67 years) without continuous prednisone or surveillance (n=188; median age 67 years). The primary endpoint was increasing prostate-specific antigen (PSA) levels 2 ng/mL above the nadir value.

After 104 months since randomization, 58 docetaxel-treated patients and 57 surveillance controls had fulfilled the study endpoint of PSA progression 2.0 ng/mL above nadir. The median time to progression, death or last follow-up in the respective treatment arms was 60 and 59 months.

Kaplan-Meier analysis revealed no significant difference in the risk of progression over time between the two treatment groups (p=0.6). The 5-year biochemical progression rate estimates were 31 percent for the docetaxel group and 28 percent for the surveillance group.

Forty-three deaths occurred during the trial, 20 of which were in the docetaxel arm and 23 were in the surveillance arm. Nine and seven, respectively, were related to prostate cancer. The resulting 5-year estimated mortality rate was 10 percent for both groups.

Cox multivariate analysis further confirmed the null effect of treatment arm assignment on PSA progression (docetaxel vs surveillance: hazard ratio, 1.14, 95 percent confidence intervals, 0.79–1.64; p=0.5).

“Our result does not support the use of docetaxel after radical RT for intermediate- or high-risk prostate cancer,” said researchers.

Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.